Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study

Journal of Bone and Mineral Research

Volumn 27, Issue 4, 2012, Pages 789-796

  Kim, Seo Young ^a   Schneeweiss, Sebastian ^a   Liu, Jun ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

disease modifying antirheumatic drugs; fracture; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; BENZODIAZEPINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OPIATE; PENICILLAMINE; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; TIOGUANINE;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; DRUG EFFECT; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIP FRACTURE; HOSPITALIZATION; HUMAN; HUMERUS FRACTURE; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PELVIS FRACTURE; POPULATION RESEARCH; PRESCRIPTION; RHEUMATOID ARTHRITIS; RISK FACTOR; UNITED STATES; WRIST FRACTURE;

ANTIRHEUMATIC AGENTS; BONE DENSITY; CANADA; COHORT STUDIES; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84863360940     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1489     Document Type: Article

References (51)

1. Kim S, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH,. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010; 12 (4): R154.
2. Lane N, Pressman A, Star V, Cummings SR, Nevitt MC,. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1995; 10 (2): 257-63.
3. van Staa T, Geusens P, Bijlsma J, Bijlsma JW, Leufkens HG, Cooper C,. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 3104-12. (Pubitemid 44622079)
4. Coulson K, Reed G, Gilliam B, Kremer JM, Pepmueller PH,. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009; 15 (4): 155-60.
5. de Jong Z, Munneke M, Lems W, Zwinderman AH, Kroon HM, Pauwels EK, Jansen A, Ronday KH, Dijkmans BA, Breedveld FC, Vliet Vlieland TP, Hazes JM,. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum. 2004; 50 (4): 1066-76. (Pubitemid 38480816)
6. Oelzner P, Schwabe A, Lehmann G, Eidner T, Franke S, Wolf G, Hein G,. Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int. 2008; 28 (11): 1143-50.
7. Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S,. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000; 27 (11): 2582-9.
8. Barnabe C, Hanley D,. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum. 2009; 39 (2): 116-22.
9. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G,. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008; 93 (5): 1952-8. (Pubitemid 351656543)
10. McLean R,. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009; 7 (4): 134-9.
11. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, Nanes MS,. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000; 141 (11): 3956-64.
12. Taichman R, Hauschka P,. Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation. 1992; 16 (6): 587-601.
13. Hock J, Krishnan V, Onyia J, Bidwell JP, Milas J, Stanislaus D,. Osteoblast apoptosis and bone turnover. J Bone Miner Res. 2001; 16 (6): 975-84. (Pubitemid 32467141)
14. Koh J, Khang Y, Jung C, Bae S, Kim DJ, Chung YE, Kim GS,. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int. 2005; 16 (10): 1263-71. (Pubitemid 41396955)
15. Maugeri D, Russo M, Franzé C, Motta V, Motta M, Destro G, Speciale S, Santangelo A, Panebianco P, Malaguarnera M,. Correlations between C-reactive protein, interleukin-6, tumor necrosis factor-alpha and body mass index during senile osteoporosis. Arch Gerontol Geriatr. 1998; 27 (2): 159-63. (Pubitemid 28442175)
16. Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z,. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Menopause. 2009; 16 (5): 950-5.
17. Buckley L, Leib E, Cartularo K, Vacek PM, Cooper SM,. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1997; 24 (8): 1489-94. (Pubitemid 27320687)
18. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T,. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008; 67 (3): 353-7. (Pubitemid 351281270)
19. Güler-Yüksel M, Allaart C, Goekoop-Ruiterman Y, de Vries-Bouwstra JK, van Groenendael JH, Mallée C, de Bois MH, Breedveld FC, Dijkmans BA, Lems WF,. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009; 68 (3): 330-6.
20. Haugeberg G, Conaghan P, Quinn M, Emery P,. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009; 68 (12): 1898-901.
21. Eekman D, Vis M, Bultink I, Kuik DJ, Voskuyl AE, Dijkmans BA, Lems WF,. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70 (2): 389-90.
22. Hoff M, Kvien T, Kälvesten J, Elden A, Kavanaugh A, Haugeberg G,. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis. 2009; 68 (7): 1171-6.
23. Lange U, Teichmann J, Müller-Ladner U, Strunk J,. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford). 2005; 44 (12): 1546-8. (Pubitemid 41742473)
24. Serelis J, Kontogianni M, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN,. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol. 2008; 27 (6): 795-7.
25. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M,. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006; 1069: 420-7. (Pubitemid 43989885)
26. Vis M, Havaardsholm E, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF,. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65: 1495-9. (Pubitemid 44629129)
27. Vis M, Voskuyl A, Wolbink G, Dijkmans BA, Lems WF;, OSTRA Study Group. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis. 2005; 64: 336-7. (Pubitemid 40193646)
28. Wijbrandts C, Klaasen R, Dijkgraaf M, Gerlag DM, van Eck-Smit BL, Tak PP,. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009; 68: 373-6.
29. Kim S, Servi A, Polinski J, Mogun H, Weinblatt ME, Katz JN, Solomon DH,. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011; 13 (1): R32.
30. Ray W, Griffin M, Fought R, Adams ML,. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992; 45 (7): 703-14.
31. Deyo R, Cherkin D, Ciol M,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45 (6): 613-9.
32. Schneeweiss S, Seeger J, Maclure M, Wang PS, Avorn J, Glynn RJ,. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001; 154 (9): 854-64. (Pubitemid 33000813)
33. Lin D, Wei L, Ying Z,. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993; 80 (3): 557-72.
34. Gravallese E, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR,. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000; 43 (2): 250-8. (Pubitemid 30395732)
35. O'Regan S, Melhorn D, Newman A,. Methotrexate-induced bone pain in childhood leukemia. Am J Dis Child. 1973; 126 (4): 489-90.
36. Ragab A, Frech R, Vietti T,. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer. 1970; 25 (3): 580-5.
37. Mäenpää H, Soini I, Lehto M, Belt EA,. Insufficiency fractures in patients with chronic inflammatory joint diseases. Clin Exp Rheumatol. 2002; 20 (1): 77-9. (Pubitemid 34213739)
38. Alonso-Bartolomé P, Martínez-Taboada V, Blanco R, Rodriguez-Valverde V,. Insufficiency fractures of the tibia and fibula Semin Arthritis Rheum. 1999; 28 (6): 413-20.
39. di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M, la Corte R, di Matteo L, Canesi B, Caminiti M, Broggini M, Adami S,. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol. 2004; 31 (7): 1305-9. (Pubitemid 38879193)
40. Cranney A, McKendry R, Wells G, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD,. The effect of low dose methotrexate on bone density. J Rheumatol. 2001; 28 (11): 2395-9. (Pubitemid 33031967)
41. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME,. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone. 2004; 35 (5): 1200-7. (Pubitemid 39487367)
42. Hippisley-Cox J, Coupland C,. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009; 339: b4229.
43. Hoff M, Kvien T, Kälvesten J, Elden A, Kavanaugh A, Haugeberg G,. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord. 2011; 12: 54.
44. Marotte H, Pallot-Prades B, Grange L, Pallot-Prades B, Garin J, Grange L, Miossec P, Tebib J, Berger F, Nissen MJ, Juvin R, Morel F, Gaudin P,. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007; 9 (3): R61.
45. Kawai V, Grijalva C, Arbogast P, Curtis JR, Solomon DH, Delzell E, Chen L, Ouellet-Hellstrom R, Herrinton L, Liu L, Mitchel EF Jr, Stein CM, Griffin MR,. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis. Arthritis Care Res. 2011; 63: 1415-24.
46. Curtis J, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A,. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010; 40 (1): 2-14.
47. Csizmadi I, Collet J-P,. Bias and confounding in pharmacoepidemiology. In:, Strom B, Kimmel S, editors. Textbook of pharmacoepidemiology. London: John Wiley & Sons, Ltd; 2006. p. 167-71.
48. Ziadé N, Jougla E, Coste J,. Using vital statistics to estimate the population-level impact of osteoporotic fractures on mortality based on death certificates, with an application to France (2000-2004). BMC Public Health. 2009; 9: 344.
49. Goodman S, Berlin J,. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994; 121 (3): 200-6. (Pubitemid 24225638)
50. Schneeweiss S, Avorn J,. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005; 58 (4): 323-37. (Pubitemid 40601980)
51. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158 (9): 915-20. (Pubitemid 37323253)